NEWS & EVENTS
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
MENDHAM, N.J. and ROME, ITALY | November 15, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV. The CAMs were originated and developed at IRBM in conjunction with Promidis/CNCCS (a subsidiary of IRBM), Istituto Nazionale Genetica Molecolare (INGM) and San Raffaele Hospital (OSR). These CAMs enable the selection of a new pipeline candidate, which will be the second molecule in Antios’ HBV portfolio. The total potential value of the deal to the Italian sellers/parties is up to $50 million, in addition to royalties. [Read more…] about Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
Aachen (Germany) | January 12, 2021 – The Specialty Pharma Company, PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) and its wholly owned subsidiary PAION Deutschland GmbH (collectively PAION), today announce that they entered into an exclusive license agreement with La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries (collectively La Jolla) for GIAPREZA(TM) (angiotensin II) and XERAVA(TM) (eravacycline). The agreement grants PAION an exclusive license for the commercialization of these two approved products in the European Economic Area, the United Kingdom and Switzerland (the Territories). [Read more…] about PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
Hammock Pharmaceuticals Announces Licensing Sale and Global Rights to Daré Bioscience, Inc. – Novel Product Candidate for the Treatment of Bacterial Vaginosis
Charlotte | December 6, 2018 – Hammock Pharmaceuticals Inc., TriLogic Pharma LLC and MilanaPharm LLC announced today that it has entered into a definitive agreement with Daré Bioscience Inc., under which the Daré Bioscience has acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans. [Read more…] about Hammock Pharmaceuticals Announces Licensing Sale and Global Rights to Daré Bioscience, Inc. – Novel Product Candidate for the Treatment of Bacterial Vaginosis